Table 1.
Next generation therapeutic proteins or genes and their delivery system which are in the market or in clinical trial.
| Brand name of therapeutic protein/gene | Therapeutic protein/gene | Indication | Remark | References |
|---|---|---|---|---|
| Oncaspar | Therapeutic protein (pegylated formulation of L-asparaginase; Pegaspargase) | Leukaemia | USFDA-approved in 1994 | [50] |
|
| ||||
| PEG-INTRON | Therapeutic protein (pegylated formulation of IFN-a2B; Peginterferon alfa-2b) | Hepatitis C as well as malignancies | USFDA-approved in January 2000 | [51] |
|
| ||||
| PEGASYS | Therapeutic protein (pegylated formulation of IFN-a2A; Peginterferon alfa-2A) | Hepatitis C | USFDA-approved in January 2001 | [52] |
|
| ||||
| Neulasta | Therapeutic protein (pegylated formulation of Granulocyte-colony stimulating factor (GCSF) and monomethoxypolyethylene glycol; Pegfilgrastim) | Neutropenia | USFDA-approved in January 2002 | [53] |
|
| ||||
| Mircera | Therapeutic protein (pegylated formulation of Erythropoietin (EPO); Epoetin beta-methoxy polyethylene glycol) | Anemia associated with kidney disease | USFDA-approved in January 2007 | [54] |
|
| ||||
| — (No brand name available) | Therapeutic gene (RNAi therapeutics delivery of ALN-PCS02 using SNALP liposome) | Hypercholesterolemia | Clinical trial | [55] |
|
| ||||
| Glybera | Therapeutic gene (alipogene tiparvovec used adeno-associated virus serotype 1 (AAV1) viral vector delivery) | Familial lipoprotein lipase deficiency (LPLD, synonym: type I hyperlipidaemia). | First gene-therapy medicine and approved by all 27 European Union member states | [56] |